Franca Ligas

发表

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

A. Baruchel, Abraham I. Bassan, G. Vassal, 2021, European journal of cancer.

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

K. Norga, K. Wilner, Martha Donoghue, 2021, European journal of cancer.

Psychosocial risk factors for suicidality in children and adolescents

J. Buitelaar, J. Castro-Fornieles, K. Aitchison, 2019, European Child & Adolescent Psychiatry.

Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

S. Knudsen, Martha Donoghue, G. Vassal, 2022, European journal of cancer.

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

S. Armstrong, M. Rivera, K. Stegmaier, 2020, European journal of cancer.

Development and psychometric properties of the Suicidality: Treatment Occurring in Paediatrics (STOP) Suicidality Assessment Scale (STOP-SAS) in children and adolescents

J. Glennon, J. Buitelaar, J. Castro-Fornieles, 2016, BMC Pediatrics.

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

K. Norga, D. Faller, G. Vassal, 2020, European journal of cancer.

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.

W. Klapper, K. Norga, B. Burkhardt, 2019, European journal of cancer.

ACCELERATE and EMA Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children Authors

W. Klapper, K. Norga, B. Burkhardt, 2019 .

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

Sara M. Federico, M. Kool, G. Vassal, 2023, European journal of cancer.

Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study

A. Pani, R. Ardau, M. Del Zompo, 2013, BMC Medicine.

Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.

D. Juric, Martha Donoghue, L. Marshall, 2024, European journal of cancer.

Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE

K. Norga, L. Marshall, P. Blanc, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.

A. Jenkner, K. Norga, Martha Donoghue, 2020, European journal of cancer.

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

G. Rossato, G. Vassal, O. Witt, 2022, European journal of cancer.